What's New Since Our Last Report

Our prior coverage catalogued a cluster of cancer breakthroughs hitting in a single week. Several of those threads have developed with new specifics, new names, and new data.

---

Daraxonrasib: FDA Says 'Breakthrough,' MSK Calls It a 'Landmark Shift'

The drug daraxonrasib — which targets mutations in the RAS gene — has received FDA Breakthrough Designation for pancreatic cancer. This is not a full approval, but rather a signal that the FDA believes the drug may offer a substantial improvement over existing therapies and has agreed to expedite its review.

MSK gastrointestinal oncologist Dr. Eileen O'Reilly led a phase 1/2 clinical trial of the drug and reported results in April 2026 at the Annual Meeting of the American Association for Cancer Research. Her assessment: "This drug is potentially going to be a landmark shift in how we treat pancreatic cancer."

KRAS mutations drive over 90% of pancreatic cancer. For decades, that mutation was considered essentially undruggable. Scientists couldn't find a clean way to block it without wrecking normal cell function.

Daraxonrasib targets RAS mutations broadly — not just one subtype — which gives it a wider potential patient base than previous narrower attempts.

The drug is taken orally, once a day. No IV infusion. No hospital stay for the treatment itself. For patients who are often elderly, already weakened, and unable to tolerate aggressive chemotherapy regimens, that's a significant difference.

According to Memorial Sloan Kettering Cancer Center, the trial included patients with stage 4 metastatic pancreatic cancer — meaning cancer that has already spread. The results were described as "encouraging." Full survival data is still being developed.

Pancreatic cancer is projected to become the second most deadly cancer in the United States by 2030, according to MSK. The current standard of care is chemotherapy — and outcomes remain grim. Median survival after a stage 4 diagnosis is typically measured in months, not years.

---

Zombie Cells: New Data, New Mechanism, New Drugs in Mouse Trials

Researchers at the MRC Laboratory of Medical Sciences and Imperial College London published findings in Nature Cell Biology on May 12, 2026 on senescent cells, sometimes called "zombie cells." These are cells that stop dividing but stay metabolically active and release inflammatory signals that damage surrounding tissue, promote cancer spread, and help tumors become resistant to treatment.

Chemotherapy itself creates more of these zombie cells. Standard treatment stops tumors from growing by halting rapid cell division. But in doing so, it floods tissue with senescent cells that then work against long-term outcomes.

Lead author Mariantonietta D'Ambrosio, a postdoctoral researcher at LMS, explained the problem: "With time you also see the negative side of the senescent cells, because they secrete a lot of factors that influence neighboring cells and induce even more proliferation, metastasis, and recruitment of bad participants."

The new drugs work by targeting GPX4 — a protective protein that senescent cells rely on to survive. These cells sit right on the edge of iron-triggered self-destruction (a process called ferroptosis), and GPX4 keeps them from tipping over. Remove GPX4 protection, and they self-destruct.

In mouse models, the approach reduced tumor size and boosted survival rates. According to ScienceDaily reporting on the MRC research, the drugs are designed to work alongside existing chemotherapy — not replace it — which lowers the regulatory and adoption barrier significantly.

Mouse results have not yet been tested in humans. The mechanism is novel, the target is well-defined, and the logic is sound, but translation to human trials remains uncertain.

---

Cleveland Team Finds New Pathway — Before It Becomes a Drug

The Harrington Discovery Institute at University Hospitals in Cleveland published research in Science Signaling identifying a new molecular pathway that could become tomorrow's drug targets.

The research focuses on how cancer cells manage to keep growth factor receptors — proteins like EGFR and HER2 — continuously active on their surface. These receptors are the reason cancers like lung, breast, and colorectal become aggressive. Several existing drugs already target them. The problem is drug resistance: cancer cells eventually adapt and work around the block.

The Cleveland team identified that a Golgi apparatus protein called GOLPH3, working in tandem with a myosin motor protein called MYO18A, physically moves these receptors from inside the cell to the cell membrane — keeping the cancer's signaling machinery running even when drugs try to shut it down.

They found the cellular loading dock that keeps resupplying the receptor supply. Researchers now know what to target to cut that supply line.

No drug candidates have been named, and no clinical trial has been announced. But this upstream research is where breakthroughs begin. The significance is that existing therapies that target EGFR and HER2 could be paired with future drugs targeting GOLPH3 or MYO18A to prevent the resistance that eventually defeats first-line treatment.

---

What Mainstream Coverage Is Missing

Most outlets either ignore this research entirely or reduce it to breathless "cure for cancer" framing. Both approaches serve readers badly.

The reality is a pipeline — multiple mechanisms, multiple drug candidates, multiple stages of testing. Daraxonrasib is furthest along: FDA-designated, phase 1/2 data presented, human patients already enrolled. The zombie cell research is compelling but still in mice. The Cleveland work is foundational science.

None of this is a cure. All of it is progress. Understanding the difference is what separates useful health journalism from noise.

---

What Comes Next

For the roughly 60,000 Americans diagnosed with pancreatic cancer each year, daraxonrasib represents the most concrete near-term hope. An oral drug that doesn't require chemotherapy tolerance, targeting the mutation driving 90% of cases, with FDA expedited review underway — offers real promise.

For cancer patients broadly, the zombie cell research could eventually change how oncologists follow up after chemotherapy. The Cleveland pathway discovery is the kind of foundational work that turns into a drug 10 years from now.

Multiple mechanisms are being pursued in parallel, across different stages of development.